多激酶抑制剂新辅助治疗局部晚期分化型甲状腺癌:系统综述
该系统综述纳入23项观察性研究共119例局部晚期分化型甲状腺癌患者,评估多激酶抑制剂新辅助治疗对手术和肿瘤学结局的影响。仑伐替尼最常用,肿瘤体积缩小25%至87%,部分缓解率33.3%至76.9%,114例中95例(83.3%)成功手术。结论认为可能提高切除率,但证据质量低。
要点
- 新辅助MKI可使局部晚期DTC肿瘤体积缩小25%至87%。
- 部分缓解率为33.3%至76.9%,进展仅7例。
- 114例中95例(83.3%)在新辅助MKI后接受手术。
核心结论
- 新辅助MKI可能提高局部晚期DTC的切除率。
- 总体证据质量低,需前瞻性研究确认。
研究设计与样本
- 系统综述检索PubMed、Cochrane Library、Scopus和EMBASE四个数据库,无时间限制。
- 纳入23项观察性研究(12例病例报告、9项病例系列、2项前瞻性II期研究),共119例接受新辅助MKI的局部晚期DTC患者。
主要发现
- 仑伐替尼是最常用的MKI,其次为索拉非尼。
- 肿瘤体积缩小范围为25%至87%。
- 部分缓解率范围为33.3%至76.9%。
- 进展性疾病仅报告7例。
- 114例不可手术或可手术但围手术期并发症风险高的患者中,95例(83.3%)能够接受手术。
临床怎么用
- 对局部晚期DTC,可考虑新辅助MKI以缩小肿瘤并提高可切除性。
- 治疗决策需结合多学科评估,并认识到当前证据质量低。
局限性
- 纳入研究以病例报告和病例系列为主,仅2项前瞻性II期研究。
- 总体证据质量低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The use of multikinase inhibitors (MKIs) in thyroid cancer has been established to downsize and facilitate resection of poorly differentiated, differentiated high-grade, anaplastic, and medullary thyroid cancer. Case reports and case series have suggested the potential use of MKIs as neoadjuvant therapies for locally advanced differentiated thyroid cancer (DTC). Our objective was to review available studies and assess if neoadjuvant therapy with MKI can improve surgical and oncological outcomes in patients with locally advanced DTC. Methods: A systematic search of four different databases (PubMed, Cochrane Library, Scopus, and EMBASE) with no time restrictions was performed to identify relevant observational studies evaluating patients with locally advanced DTC who received neoadjuvant therapy before surgery with MKI (PROSPERO ID: CRD420251012812). Results: A total of 119 participants from 23 observational studies (12 case reports, 9 case series, and 2 prospective phase II studies) were included. Lenvatinib was the most frequently used MKI, followed by sorafenib. Tumor volume reduction ranged from 25% to 87%, and partial response rates ranged between 33.3% and 76.9%, whereas progressive disease was described only in seven cases. Of 114 patients with inoperable or potentially resectable tumors with associated high perioperative morbidity, 95 (83.3%) were able to undergo surgery. Conclusions: Neoadjuvant MKIs in locally advanced DTC may improve resection rates. The overall low quality of evidence prompts further prospective studies to confirm these findings.
引用
- Bauzon J, Ponce de Leon-Ballesteros G, Lincango E, et al. Neoadjuvant Therapy with Multikinase Inhibitors for Locally Advanced Differentiated Thyroid Cancer: A Systematic Review. Thyroid. 2025. PMID: 40803667. doi:10.1177/10507256251367286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。